This patent disclosure relates generally to injection devices and, more particularly to multi-dosing injection devices for sequentially delivering several fractions of a total volume of injectable fluid available in a syringe.
There are a number of current and emerging clinical applications that require delivering at only a fraction of the total available injectable fluid volume using a syringe a time. These dose volume fractions can range from microliters through milliliters. These include applications in disciplines such as ophthalmology, oncology, dental, dermatology, nephrology, vaccines, rheumatology, etc. Administration of injections may be required at multiple locations within an organ or tumor. For example, in case of skin carcinomas, injections may be required in multiple lesions to be treated.
The most common approach to splitting the total deliverable volume into multiple doses is by using injection volume gradations on the syringe as a reference. For example, to split a 1 mL drug solution in a syringe into 10 fractions of 0.1 mL each, the clinician administering the drug solution can achieve 10 injections of 0.1 mL by controlling the start of injection position and end of injection position. The difference between the aforementioned positions yields the volume to be injected.
The cognitive burden placed on the clinician includes calculation of injection dose volume for each injected dose volume and memorization of start of dose and end of dose positions for each injected volume. Simultaneously, clinician is required to ensure that the dose is injected in the correct location. Cognitive burdens associated with conventional injection systems could pose potential dexterity challenges with injection procedure, which may diminish effectiveness of injected therapy or cause potential harm. This problem becomes particularly acute for injectable drugs with a narrow therapeutic window or investigational treatments where treatment efficacy is to be determined (or unknown).
In order to minimize the cognitive burden with using a single conventional syringe for multiple doses, a clinician could have multiple syringes filled with therapeutic agent prefilled and ready to inject only the desired amount. There is inherent inefficiency and waste in this approach since there is drug priming required for each of the syringes, and hence increase cost of treatment. Also, the procedure would now involve multiple personnel to refresh and replace the syringes being used. This additional handling could also pose exposure risks to clinical personnel in case of potent treatments involving virus, immunotherapeutic agents, chemotherapies, etc.
The delivery conduit is typically an injection needle (or rigid delivery cannula), a catheter or a luer lock access site. Any delivery system is first primed to ensure that all of the air in the delivery conduit is purged. In case of applications requiring splitting the dose into equal fractions of the total available dose in the syringe, priming is done only once prior to delivery of the first fractional dose.
In addition to using dose markings, various device-based approaches have been proposed to split the total available volume in the syringe. These device-based approaches typically require the stereotactic reference to change with administration of each fraction of the dose; this would require the clinician to adjust their grip with injection of each fraction. While it is possible it maintain the same differential between start and end of dose positions, the absolute positions of the start and end of dose (stereotactic reference) is constantly changing with delivery of each dose fraction. This potential lack of stability can be particularly problematic in applications involving injections in sensitive organs, and in applications such as in cosmetic dermatology, where any disturbance during injection when using a needle can cause a cosmetic defect and/or injury. This issue of constantly changing stereotactic reference can also pose an extra challenge and complexity in incorporating such a device with a robotic delivery system.
Many device-based approaches also require an extra step from the user to transition from delivery of one fractional dose to another fractional dose. While this can be accommodated in some applications, other applications, such as injections in sub-retinal space in the eye, require minimizing number of steps involved. Device designs that do not require an additional step to deliver the next fractional dose would also be more compatible with a robotic delivery system.
Some applications require administration into a high pressure line, such as injection in a blood vessel. This requires that there be no ingress of blood back into the syringe. This is now achieved by clinician maintaining pressure on a syringe plunger rod. If pressure is not maintained, there is potential of a blood spill when the plunger rod is pushed back to the non-patient end, and hence risk of blood exposure to the healthcare professional.
Some other applications require accurate, precise delivery of sub-milliliter fractional doses. This can be particularly challenging without a device to split the dose from a syringe, which is typically used to deliver milliliter drug dose volumes into equal microliter fractions. Even within microliter delivery, the problem with delivering an accurate, precise dose becomes more acute with fractional doses of 100 microliters or less. Accuracy and precision of delivered fractional dose is also critical in applications involving injection of potent drugs that have a very narrow therapeutic window or drugs that may be harmful effects outside of the target delivery area.
The disclosure describes, in one aspect, a controlled multidosing delivery device for use with a syringe including a barrel, plunger stopper, and a delivery conduit. The controlled multidosing delivery device includes a housing, a plunger rod and a drive shell. The housing defines an axis and including a proximal end, a distal end, an axially extending chamber including a first opening to the proximal end of the housing and a second opening to the distal end of the housing. The distal end of the housing is adapted for attachment to the syringe barrel along the axis. The plunger rod includes an elongated shaft having a proximal end and a distal end. A contact button is disposed at the proximal end of the elongated shaft, and a pusher feature is disposed at the distal end of the elongated shaft. A portion of the elongated shaft is disposed within the axially extending chamber of the housing. The proximal end of the elongated shaft extends at least partially from the proximal end of the housing with the contact button being disposed external to the housing. A biasing structure is disposed to bias the contact button away from the housing. A retaining structure is adapted to inhibit removal of the plunger rod through the first opening of the housing and permit the plunger rod to translate axially a predetermined distance. The drive shell is disposed within the axially extending chamber of the housing. The drive shell includes a head disposed for translation along the axis, and a plurality of engagement surfaces. The pushing feature of the plunger rod is biased toward at least one of the engagement surfaces. The pushing feature is disposed to engage the at least one of the engagement surfaces to translate the drive shell in a distal direction. A retention feature includes at least one retention finger and a plurality of retention surfaces. The retention feature is adapted to inhibit proximal movement of the drive shell within the axially extending chamber when retention finger is engaged with at least one of the plurality of retention surfaces. At least one of the at least one retention finger and the plurality of retention surfaces is associated with the drive shell; the other of the retention finger and the plurality of retention surfaces is associated with the housing. Depression of the contact button axially translates the elongated shaft and pusher feature in engagement with the at least one of the engagement surfaces in a distal direction along the axis to translate the drive shell in the distal direction based upon the predetermined distance to cause corresponding movement of the plunger stopper within the barrel for a dose delivery, whereby the at least one retention finger engages with at least one of the plurality of retention surfaces to maintain an axial position of the drive shell in the housing following movement of the drive shell in the distal direction, and whereby the biasing structure translates the plunger rod in the proximal direction following translation of the drive shell.
The disclosure further describes, in another aspect, a method of assembling the controlled multidosing delivery device including inserting the drive shell into the axially extending chamber in the housing, inserting the distal end of the plunger rod into the housing to position the contact button for depression, and coupling a retaining structure with the plunger rod to prevent removal of the plunger rod from the housing.
In yet another aspect, the disclosure describes various applications of the disclosed device.
In still a further aspect, the disclosure describes a method of using a controlled multiple dosing device, such as the controlled multidosing delivery devices disclosed herein with a syringe to administer a therapeutic fluid to a brain.
This disclosure relates to a controlled multidosing delivery device utilized to sequentially delivering several fractions of the total available injectable fluid available in a syringe; these injection fraction volumes may be equal or unequal. For the purposes of this disclosure, the term “injectable fluid” includes any injectable fluid, including, but not limited to therapeutic agent, injectable substance, drug solution, stem cells, etc., and vice versa, unless otherwise apparent from the context. For the purposes of this disclosure, the term “delivery conduit” is a structure through which an injectable fluid may be delivered, including, but not limited to, a cannula, a needle, catheter, an elongated tubular structure, etc., and vice versa, unless otherwise apparent from the context. Also for the purposes of this disclosure, the terms “user” and “clinician” and “operator” are used interchangeably and include any individual or individuals operating the device unless otherwise apparent from the context.
Turning to
Referring to the cross-section of
The controlled multidosing delivery device 100 is provided for attachment to the syringe 102. The controlled multidosing delivery device 100 includes a housing 118, which includes a proximal end 119 and a distal end 120. The distal end 120 of the housing 118 is adapted for coupling to the proximal end 105 of the syringe 102. The housing is illustrated in greater detail in
In order to couple the flange 106 with the housing 118, one or more clips 124 are provided. As seen most clearly in
In order to couple the clips 124 along with proximal end 105 of the syringe 102 to the distal end of the housing 118, mating structures 130 are provided (see
To further facilitate secure coupling of the syringe 102 with the housing 118, an elastomeric washer 140 may be provided (see
While the coupling of the syringe 102 with the housing 118 has been described and illustrated in connection with a plurality of clips 124 disposed around a proximal end 105 of the barrel 104 and the flange 106 of syringe 102 and received in channel 122 at a distal end of the housing 118, it will be appreciated by those of skill in the art that alternative coupling arrangements may be provided. For example, a flange of a syringe may be seated against a distal end of a device housing, and one or more clips clamped around the outer surfaces of both the distal end of the housing and the flange. By way of further example, the device housing may include a transversely disposed slot, such that the flange of a barrel may be moved transversely into position relative to the barrel.
In order to assist in assembly of the syringe 102, a wrench tool 142 may be provided. As illustrated, for example, in
The controlled multidosing delivery device 100 further includes a drive shell 154 and a plunger rod 156. Turning first to the plunger rod 156, which is illustrated in greater detail in
In assembly, the elongated shaft 158 is received in a through hole 164 in a proximal wall 166 of the housing 118 (see
Similarly, the distal portion 170 of the elongated shaft 158 may include any appropriate cross-section, so long as the elongated shaft 158 provides sufficient strength to perform its pushing function. The distal portion 170 of the illustrated embodiment includes a narrowed cross-section relative to the cross-section of the proximal portion 168. In this embodiment, the distal portion 170 includes a rectangular cross-section, although the cross-section may be other than illustrated. The pushing feature 162 at the distal end of the elongated shaft 158 protrudes from a side surface 174 of the distal portion 170 of the elongated shaft 158 to present a relatively sharp finger 176 (see
Turning now to
In order to provide translational motion to the head 180, the elongated drive arm 182 includes a plurality of forward drive engagement steps 190. The forward drive engagement steps 190 include an engagement surface 192 and a ramp 194. The engagement surface 192 faces a proximal end 196 of the drive shell 154. As may be seen in the cross-section of
In order to ready the controlled multidosing delivery device 100 to provide subsequent injection strokes, the plunger rod 156 is biased in the proximal direction relative to the housing 118. In order to bias to plunger rod 156 away from the housing 118, a biasing structure such as spring 163 is provided between the plunger rod 156 and the housing 118. As may be seen in
Inasmuch as the plunger rod 156 is biased toward its original axial position, the finger 176 rides along the ramped surface 194 disposed adjacent the engagement surface 192 utilized for the injection, moving the finger 176 inward. The elongated shaft 158 of the plunger rod 156 outward under bias as the finger 176 reaches the next engagement surface 192 of the drive shell 154. In this engaged position, the controlled multidosing delivery device 100 and syringe 102 are ready to dispense the next measured injection of fluid from the syringe 102 upon depression of the plunger rod 156.
As is likewise apparent from
In operation, axial movement of the plunger rod 156 and engagement of the pushing feature 162 with an engagement surface 192 of the drive shell 154 advances the drive shell 154 in the distal direction within the housing 118. As the drive shell 154 advances within the housing 118, the elongated retention arm 184 of the drive shell 154 deflects inward as the retention finger 206 rides along a ramped surface 204 of the housing 118. Inasmuch as the elongated retention arm 184 is biased to its outward, free position, as the retention finger 206 reaches the end of the ramped surface 204, the retention finger 206 moves outward to engage the next engagement ledge 202 of the housing 118 to prevent the drive shell 154 from movement in a proximal direction relative to the housing 118. In this way, the retention finger 206 advances from engagement ledge 202 to engagement ledge 202 of the sawtooth pattern with each end of dose. While the engagement ledges 202 of the illustrated embodiment are disposed at a right angle to the adjacent ramped surface 204 and the longitudinal axis of movement of the drive shell 154 within the housing 118, it will be appreciated that the angle at the defined peak may be other than as illustrated, so long as a secure engagement of the retention finger 206 is provided with the ledge 202.
The number of teeth or peaks presented between adjacent ramped surfaces 204 and engagement ledges 202 defines than the number of injections that may be administered using the controlled multidosing delivery device 100. If an initial movement of the plunger rod 156 and the drive shell 154 is utilized in a priming operation, then the number teeth or peaks is one greater than the number of injections that may be administered. Thus, in the illustrated embodiment, the controlled multidosing delivery device 100 may be utilized to dispense fluid from the associated syringe 102 eight times, or the controlled multidosing delivery device 100 may be utilized to prime the syringe 102, and to administer seven injections.
Referring to
In order to retain the elongated shaft 158 of the plunger rod 156 in position within the housing 118, a retaining arrangement is provided. In the illustrated embodiment, the elongated shaft 158 is provided with a through hole 212, and a retaining pin 214 is inserted into the through hole 212 orthogonal to the axis of the plunger rod 156. In assembly, the plunger rod 156 is depressed slightly to provide ready access to the through hole 212, and to properly position the spring 163 before the retaining pin 214 is inserted. Inasmuch as the length of the retaining pin 214 is greater than the length of the through hole 212, the end(s) of the retaining pin 214 protruding from the through hole 212 act to retain the plunger rod 156 within the housing 118. Further, inasmuch as the effective length of the retaining pin 214 within the through hole 212 is less than the depth of the axially extending chamber 200 of the housing 118, the plunger rod 156 may be axially translated within the housing 118 between the elongated drive arm 182 and the elongated retention arm 184 of the drive shell 154.
Referring to
The syringe 102 may coupled to the housing 118 as explained above. It will be appreciated that operation of the controlled multidosing delivery device 100 does not require that the cover 220 be positioned on the housing 118. Moreover, the syringe 102 is not required to be coupled to the housing 118 only after the placement of the cover 220 with the housing 118. It is noted, however, that the placement of the cover 220 on the housing 118 covers and protects the operation of the internal structures of the housing 118, while maintaining a clean environment.
The housing 118 may additionally include a flange 230 positioned at the proximal end 119 of the housing 118. In at least some embodiments, the flange 230 may extend from either side of the housing 118 a sufficient distance to provide engagement surfaces for the user's fingers during operation. It will be appreciated that the flange 230 may afford the user more stability during the injection procedure. The flange 230 may also be used to aid attachment of the controlled multidosing delivery device 100 to a stereotactic frame or robotic arm. Alternatively or additionally, further structure may be provided with the housing 118 to facilitate coupling to a stereotactic frame or robotic arm.
An exemplary operation of the controlled multidosing delivery device 100 and coupled syringe 102 is illustrated in
As the drive shell 154 is axially translated relative to the housing 118 during dispensing, the retention finger 206 of the drive shell 154 is moved against its outward bias and rides along a ramped surface 204 within the channel 122 of the housing 118 until such time as the retention finger 206 reaches an engagement ledge 202 within the channel 122. Under the force of the bias, the retention finger 206 then moves outward to engage the subsequent engagement ledge 202. This engagement between the retention finger 206 and the engagement ledge 202 acts to prevent movement of the drive shell 154 in a proximal direction relative to the housing 118. In at least some embodiments, this movement of the retention finger 206 outward and into engagement with the engagement ledge 202 provides an audible click, which may provide the user with an additional indication that the dose has been delivered.
As the contact button 160 is depressed during dose delivery, the biasing structure or spring 163 is compressed. As pressure is released from the contact button 160, the force of the spring 163 returns the contact button 160 to the start of dose position 240. As the plunger rod 156 concurrently translates axially in the proximal direction, the distal portion 170 of the elongated shaft 158 moves against a bias of the finger 176 of the pushing feature 162 into engagement with an engagement surface 192 of the drive shell 154, sliding the finger 176 along the adjacent ramp 194 until the finger 176 is again biased into contact with the next engagement surface 192. The components of the controlled multidosing delivery device 100 and coupled syringe 102 are then in position for delivery of the subsequent dose. As may be seen in
Thus, when the plunger rod 156 is sequentially depressed by the user, the retention finger 206 continues to advance with the advancement of the drive shell 154 until the retention finger 206 is advanced to a final location that is the most distally disposed engagement ledge 202 of the housing 118. Accordingly, any subsequent attempt by the user to depress the plunger rod 156 does not translate into any further advancement of the plunger stopper 116 within the barrel 104 of the syringe 102. The controlled multidosing delivery device 100 and coupled syringe 102 can then be disposed appropriately.
Referring to
Those of skill in the art will appreciate, however, that windows may be alternatively or additionally disposed with the controlled multidosing delivery device 257 and coupled syringe 258. As illustrated in
Those of skill in the art will appreciate that various elements of the structures described in detail herein may be modified while still coming within the purview of the appended claims. For example, an alternate embodiment of an arrangement for limiting proximal axial movement of a drive shell 276 within a housing is illustrated in
The controlled multidosing delivery devices and syringes of this disclosure may be utilized in various applications and procedures. For example, a controlled multidosing delivery device and syringe may be utilized in single site deliveries or in multiple sites in a given tissue.
It will be appreciated that at least some of the controlled multidosing delivery devices disclosed herein may be beneficial for use in emerging technologies. For example, some injectable substances are extremely potent and can potentially pose a safety risk to the user administering the treatment. A number of emerging treatments of cancer involve the injection of a therapeutic agent locally into the tumor, for example. These agents may include oncolytic viruses, PDL-1, immunotherapeutic agents and the like, which may pose such a safety risk.
Further, the use of controlled multidosing delivery devices, such as the devices disclosed herein, may provide additional benefits by allowing dose splitting of a volume of an injectable substance into smaller fractions at different sites of a target tissue. For example, tumors typically have necrosis that inhibit distribution of a therapeutic agent, thereby limiting its effectiveness. One way to overcome this is to inject in multiple sites of the tumor to enhance bioavailability and biodistribution of the therapeutic agent. Further, inasmuch as some cancer therapeutics that are designed stimulate the patient's immune system to fight cancer cells, providing multiple injections on the periphery of the cancerous lesion may provide therapeutic benefits through an enhances immune response to the tumor. The dose splitting provided by at least some of the controlled multidosing delivery devices disclosed herein may provide improved distribution of the delivered agent throughout a tumor, for example. Also, reducing the volume of each dose administered by splitting the total dose to be administer into smaller volumes may minimize the risk of drug leakage (extravasation) from the point of injection. Such multiple dosing delivery systems also may allow the clinician to focus on the anatomical aspect of the injection without diversion of clinician's cognitive faculties to the mathematical aspect of injection volume calculation. The use of a single controlled multidosing delivery device and syringe to administer injections into tumors at multiple locations for a given patient may allow the clinician to employ the same injection needle without the need for priming between injections.
Additionally, the volume of therapeutic agent is typically metered based on the size of the tumor. For example, in case of skin carcinomas, there may be multiple lesions (same and/or different size) to be treated. A device such as the controlled multidosing delivery devices disclosed, which enabling tracking of fractional doses, may alleviate the burden on the clinician to ensure that the therapeutic agent is metered accurately and appropriately.
One such example of the utilization of a controlled multidosing delivery device and syringe (collectively identified as 302) in the administration of therapeutic agents in solid tumors is illustrated in
At least some of the controlled multidosing delivery devices and syringes may be utilized to deliver a plurality of doses from a single insertion of a cannula. For example, a controlled multidosing delivery device and syringe, such as the arrangements disclosed herein, may be utilized in providing multiple injections in the brain, as illustrated, for example, in
Secured with the single-axis micromanipulator 298, the controlled multidosing delivery device and syringe 290 may be advanced only along the axis of the controlled multidosing delivery device and syringe 290, the axis being aligned with a delivery cannula of the controlled multidosing delivery device and syringe 290. The delivery cannula of the controlled multidosing delivery device and syringe 290 may then be aligned with an opening 300 in the skull 292.
Coarse manipulation of the controlled multidosing delivery device and syringe 290 may be utilized to drive the delivery cannula through the brain's meninges close to the most distal target injection site or the cannula may be insert through an incision through the brain's meninges. Once close, fine manipulation allows the clinician to dispose the tip of the delivery cannula to the predetermined injection site. The controlled multidosing delivery device and syringe 290 is utilized to deliver a first dose of the injectable solution to the predetermined injection site. The controlled multidosing delivery device and syringe 290 is moved in a retraction direction to through fine manipulation using micromanipulator to retrace the delivery cannula entry path to position the delivery cannula in the second predetermined injection site. The controlled multidosing delivery device and syringe 290 is actuated to deliver second dose through the delivery cannula to the second predetermined injection site. This process may be repeated several times as the treatment modality would require subject to the availability of injectable fluid in the controlled multidosing delivery device and syringe 290. Ultimately, the cannula is pulled out from the tissue with minimum surgical trauma to the tissue. In this way, a controlled multidosing delivery device and syringe 290 such as devices of this disclosure may be utilized to deliver a controlled volumes of an injectable solution at different depth of a site. Significantly, multiple, equal volumes may be injected at different depths via a single insertion of the delivery cannula. The delivery cannula may be rigid or flexible (like a catheter, for example), and may have a blunt or sharp tip.
It will be appreciated that one or more imaging modality may be utilized as guidance in the positioning of the delivery cannula in the brain. The utilization of a multidosing delivery device may facilitate the accurate administration of small doses of injectable fluid, such as, for example, volumes of 100 microliters or less. Several applications involving injections of cells are likely to involve sub-milliliter (microliter) injection volumes. Because of sedimentation problems with cells, treatments involving injection of nerve cells, stem cells and the like need to be concentrated. In this way, different strengths of treatment involving cells may be achieved by varying the injection volume, which would be in the order of microliters. Those of skill in the art will appreciate that the utilization of a controlled multidosing delivery device and syringe in the injection of therapeutic agent into a brain, may assist in minimizing complications from the procedure by minimizing the number of insertions through the meninges, and also help administer accurate, precise doses. Inasmuch as brain tumors are typically diffuse, treatment may be benefited from injections in more than one location. Injecting in more than one location may additionally benefit some other brain treatment applications involving injection of a fluid that includes cells (e.g., stem cells) in the brain, particularly inasmuch as cells deposited in the proximity of target injection site and may still have potential therapeutic benefit. Also, distributing cells over several locations rather than injecting all of them in one location may potentially improve nutrient flow to these cells, thereby increasing time for which the cells are viable.
As will be understood by those of skill in the art, the components of the disclosed controlled multidosing delivery devices and syringes according to this disclosure may be made by any appropriate method. For example, the drive shell, housing, cover, plunger rod and sleeve may be injection molded or 3D printed, or the like.
It will readily be understood by one having ordinary skill in the relevant art that the disclosed invention has broad utility and application. Those of skill in the art will appreciate that at least some of the controlled multidosing delivery devices according to this disclosure facilitate multi-dosing from a syringe, including multi-dosing from a prefilled syringe. In at least some of the disclosed controlled multidosing delivery devices, user's start of injection position is constant relative to the point of injection in that the contact button is returned to an original, readied position following each injection.
Further, while the structure of controlled multidosing delivery devices discussed in detail in this disclosure have been designed to delivery eight doses (or seven doses and priming), alternative embodiments consistent with the teachings of this disclosure may be structured to deliver multiple doses, but in a greater or lesser number by varying the number of forward engagement surfaces of the drive shell and the number of retention surfaces. For example, alternative embodiments may provide the delivery of two, three, four, five, six, seven, nine or more doses by providing two, three, four, five, six, seven, nine or more forward engagement surfaces of the drive shell and the two, three, four, five, six, seven, nine or more retention surfaces, respectively.
In at least some embodiments of the controlled multidosing delivery device, the stereotactic reference for start and end of fractional dose administration remains the same irrespective of dose fraction sequence index. This may allow the clinician use to focus only the injection target, and may alleviate at least a portion of the cognitive burden on the user clinician to track and/or calculate the start and end of dose delivery position.
In at least some embodiments of the controlled multidosing delivery device, the available length of travel of the plunger rod may facilitate delivery of an accurate, precise milliliter or microliter fractional dose. At least some embodiments of the controlled multidosing delivery device allow for the delivery of equal volumes of available injectable substance from a syringe.
At least some embodiments of the controlled multidosing delivery device facilitate successive delivery of a fraction of the volume of injectable substance in an associated syringe without the need for priming after initial priming. In at least some embodiments, the controlled multidosing delivery device may inhibit movement of a plunger stopper of a syringe in a proximal direction as a result of back pressure originating at a patient end.
At least some embodiments of the controlled multidosing delivery device provide a visual indication of one or more of the number of doses administered and/or remaining, and/or the volume of injectable substance administered or remaining in the associated syringe.
The controlled multidosing delivery devices may be utilized with prefilled syringes, with syringes wherein the user can draw the injectable fluid from a vial, and with combinations thereof.
Any embodiment discussed and identified as being “preferred” should be considered to be part of a best mode envisioned to illustrate the present invention. Other additional embodiments are also discussed to exemplify and illustrate variations within the scope of the disclosed invention. Moreover, adaptations, variations, modifications, and equivalent arrangements, will also be implicitly disclosed by the embodiments described herein and would also fall within the scope of the present invention disclosed herein.
It will be appreciated that the foregoing description provides examples of the disclosed system and technique. However, it is contemplated that other implementations of the disclosure may differ in detail from the foregoing examples. All references to the disclosure or examples thereof are intended to reference the particular example being discussed at that point and are not intended to imply any limitation as to the scope of the disclosure more generally. All language of distinction and disparagement with respect to certain features is intended to indicate a lack of preference for those features, but not to exclude such from the scope of the disclosure entirely unless otherwise indicated.
Recitation of ranges of values herein are merely intended to serve as a shorthand method of referring individually to each separate value falling within the range, unless otherwise indicated herein, and each separate value is incorporated into the specification as if it were individually recited herein. All methods described herein can be performed in any suitable order unless otherwise indicated herein or otherwise clearly contradicted by context.
The use of the terms “a” and “an” and “the” and “at least one” and similar referents in the context of describing the invention (especially in the context of the following claims) are to be construed to cover both the singular and the plural, unless otherwise indicated herein or clearly contradicted by context. The use of the term “at least one” followed by a list of one or more items (for example, “at least one of A and B”) is to be construed to mean one item selected from the listed items (A or B) or any combination of two or more of the listed items (A and B), unless otherwise indicated herein or clearly contradicted by context.
Accordingly, this disclosure includes all modifications and equivalents of the subject matter recited in the claims appended hereto as permitted by applicable law. Moreover, any combination of the above-described elements in all possible variations thereof is encompassed by the disclosure unless otherwise indicated herein or otherwise clearly contradicted by context.
This patent disclosure claims priority to U.S. Provisional Patent Application 62/831,487, filed Apr. 9, 2019, which is incorporated herein by reference for all purposes.
Filing Document | Filing Date | Country | Kind |
---|---|---|---|
PCT/US2020/027478 | 4/9/2020 | WO | 00 |
Number | Date | Country | |
---|---|---|---|
62831487 | Apr 2019 | US |